Last reviewed · How we verify

Bupivicaine

University of Colorado, Denver · FDA-approved active Small molecule ✓ Verified May 2026

Bupivicaine is a Small molecule drug developed by University of Colorado, Denver. It is currently FDA-approved. Also known as: Bupivicaine, Peripheral Nerve Injection, marcaine, Marcaine.

Bupivacaine is a medication used to decrease sensation in a specific small area, typically injected around a nerve or into the spinal canal's epidural space. It works by blocking the sodium channel protein type IV alpha subunit, a mechanism that is classified as a blocker.

At a glance

Generic nameBupivicaine
Also known asBupivicaine, Peripheral Nerve Injection, marcaine, Marcaine, Marcain
SponsorUniversity of Colorado, Denver
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivicaine

What is Bupivicaine?

Bupivicaine is a Small molecule drug developed by University of Colorado, Denver.

Who makes Bupivicaine?

Bupivicaine is developed and marketed by University of Colorado, Denver (see full University of Colorado, Denver pipeline at /company/university-of-colorado-denver).

Is Bupivicaine also known as anything else?

Bupivicaine is also known as Bupivicaine, Peripheral Nerve Injection, marcaine, Marcaine, Marcain.

What development phase is Bupivicaine in?

Bupivicaine is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing